January 15, 2018 Uncategorized

BD and Check-Points Receive CE Mark for Next-generation Resistant Bacteria Screening Test

FRANKLIN LAKES, N.J., and WAGENINGEN, The Netherlands, Jan. 15, 2018 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, along with Check-Points Health B.V., announced today that the companies obtained CE Mark for a next-generation molecular screening test for antibiotic-resistant carbapenemase-producing organisms (CPOs) on the fully-automated BD MAX™ System. It... Read more

January 11, 2018 Uncategorized

Society for Laboratory Automation

02. February 2018 – 07. February 2018 Visit Greiner Bio-One at Booth 629 at the SLAS in San Diego! SLAS2018 is the annual flagship International Conference and Exhibition from SLAS. Through a unique combination of education, access to innovative technologies and intelligent peer networking, SLAS2018 delivers unmatched value for professionals and students looking to discover... Read more

January 11, 2018 Uncategorized

First imaging agent of its kind now approved in Canada to help physicians in the diagnosis of patients with suspected Parkinsonian Syndromes

CHALFONT ST. GILES, UK, 11 January 2018 – GE Healthcare announced today the approval in Canada of DaTscan™ (Ioflupane I 123 Injection), the first Health Canada approved radiopharmaceutical adjunct imaging agent to help physicians evaluate patients with a suspected parkinsonian syndrome (PS) such as https://www.genewsroom.com/press-releases/first-imaging-agent-its-kind-now-approved-canada-help-physicians-diagnosis-patients Read more

December 22, 2017 Uncategorized

Ad-hoc Announcement of Inside Information according to Article 17 MAR

Germantown, Maryland, and Hilden, Germany, December 22, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) announces that, mainly as a consequence of the new U.S. tax legislation, it will take an extraordinary after-tax charge on net income of approximately $110-120 million (or about $0.47-$0.52 per share) in the fourth quarter of 2017, and... Read more

December 21, 2017 Uncategorized

European Commission approves Roche’s Alecensa (alectinib) as first-line treatment in ALK-positive lung cancer

ALEX (NCT02075840/B028984) is a randomised, multicentre, open-label phase III study evaluating the efficacy and safety of Alecensa versus crizotinib in treatment-naïve people with ALK-positive NSCLC whose tumours were characterised as ALK-positive by the VENTANA ALK (D5F3) CDx Assay, a companion immunohistochemistry (IHC) test developed by Roche Tissue Diagnostics. People were randomised (1:1) to receive either... Read more

December 9, 2017 Uncategorized

Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors

Basel, 09 December 2017 Roche’s Hemlibra continued to substantially reduce bleeds in people with haemophilia A with inhibitors Newly approved Hemlibra demonstrated superior efficacy compared to prior treatment with bypassing agents as prophylaxis or on-demand Nearly 95% of children who received Hemlibra experienced zero treated bleeds Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that... Read more

December 8, 2017 Uncategorized

QIAGEN to transfer U.S. listing of global shares to NYSE

Germantown, Maryland, and Hilden, Germany, December 08, 2017 – QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA) today announced that it is transferring the U.S. listing of its global shares to the New York Stock Exchange (NYSE) from the NASDAQ Global Market. The transfer to the NYSE is expected to be effective on or about... Read more